<DOC>
	<DOCNO>NCT00627471</DOCNO>
	<brief_summary>To compare term HbA1c insulin naive patient Type 2 Diabetes start insulin glargine algorithm insulin naive patient start insulin glargine physician 's standard practice . To compare term FBG insulin naïve patient start insulin glargine algorithm insulin naïve patient start insulin glargine physician 's standard practice . To compare percentage patient achieve HbA1c &lt; 7 % treatment group . To compare hypoglycaemic event ( minor , severe nocturnal ) group . To compare average insulin dose group . To compare PRO ( patient ' report outcome ) group . To compare mean change body weight treatment group .</brief_summary>
	<brief_title>Type 2 Diabetes Management With Lantus® ( Malbec : Manejo Con Lantus® de Diabéticos Tipo 2 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Patients type 2 diabetes . Patients treatment OADs ( one ) least 1 year fail metabolic control ( HbA1c &gt; 8 % &lt; 11 % ) . FBG &gt; 130 mg/dl &lt; 240 mg/dl . BMI &lt; 40 kg/m2 &gt; 25 kg/m2 . Ability willingness follow tight antidiabetic therapy perform SMBG control . C peptide &lt; 0.30 nmol/l . Unexplained weight loss 10 % body weight last 6 month . Pregnant woman woman intention become pregnant . Women childbearing potential use contraceptive protection . Breastfeeding woman . Patients use use rapid ultrarapid act insulin ; except patient use rapid ultrarapid insulin intercurrences AMI , severe infection surgery . Renal impairment define serum creatinine &gt; 1.4 mg/dl woman &gt; 1.5 mg/dl men . Hepatic impairment define GPT GOT 2x normal threshold . Likelihood require treatment study period drug permit study protocol ( non selective beta blocker systemic corticosteroid ) . History drug alcoholic abuse . Diabetic retinopathy surgical treatment 3 month prior study entry may require surgical treatment within 6 month study entry . Clinically relevant cardiovascular , gastrointestinal , hepatic , neurological , endocrine , hematological , oncologic major systemic disease make implementation protocol interpretation study result difficult , discretion investigator . Evidence uncooperative attitude , include poor compliance anti diabetic treatment . Known hypersensitivity insulin glargine . The information intend contain consideration relevant patient 's potential participation clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>